Verona Pharma plc (VRNA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3 MORE LONDON RIVERSIDE LONDON, SE1 2RE |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 404,599 | 254,882 | 271,772 | 257,366 | 270,727 | 291,415 | |||
| Cash and cash equivalents | 404,599 | 254,882 | 271,772 | 257,366 | 270,727 | 291,415 | |||
| Receivables | |||||||||
| Inventory, net of allowances, customer advances and progress billings | |||||||||
| Inventory | |||||||||
| Prepaid expense | 5,433 | 3,622 | 3,617 | 3,332 | 894 | 1,561 | |||
| Other current assets | 2,576 | 1,875 | 3,365 | 6,319 | 6,060 | 2,073 | |||
| Other undisclosed current assets | 3,684 | 11,461 | 10,954 | 9,510 | 10,150 | 11,842 | |||
| Total current assets: | 416,292 | 271,840 | 289,708 | 276,527 | 287,831 | 306,891 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 2,242 | 2,505 | 2,847 | 388 | 542 | 698 | |||
| Property, plant and equipment | 44 | 22 | 24 | 10 | 11 | 12 | |||
| Intangible assets, net (including goodwill) | 545 | 545 | 545 | 545 | 545 | 545 | |||
| Goodwill | 545 | 545 | 545 | 545 | 545 | 545 | |||
| Contract with customer, asset, after allowance for credit loss | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | |||
| Total noncurrent assets: | 17,831 | 18,072 | 18,416 | 15,943 | 16,098 | 16,255 | |||
| TOTAL ASSETS: | 434,123 | 289,912 | 308,124 | 292,470 | 303,929 | 323,146 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 23,782 | 12,920 | 7,077 | 8,220 | 9,960 | 24,940 | |||
| Accounts payable | 4,152 | 4,651 | 3,492 | 823 | 2,493 | 7,237 | |||
| Accrued liabilities | 19,630 | 8,269 | 3,585 | 7,397 | 7,467 | 17,703 | |||
| Deferred revenue | 21,322 | ||||||||
| Other liabilities | 1,200 | 736 | 435 | 416 | 444 | 509 | |||
| Other undisclosed current liabilities | 2,042 | 1,118 | 1,180 | 376 | 545 | 1,074 | |||
| Total current liabilities: | 48,346 | 14,774 | 8,692 | 9,012 | 10,949 | 26,523 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 119,687 | 48,546 | 48,374 | 19,905 | 19,857 | 19,809 | |||
| Long-term debt, excluding current maturities | 119,687 | 48,546 | 48,374 | 19,905 | 19,857 | 19,809 | |||
| Liabilities, other than long-term debt | 1,478 | 1,604 | 1,775 | 20 | 30 | 65 | |||
| Operating lease, liability | 1,478 | 1,604 | 1,775 | 20 | 30 | 65 | |||
| Other undisclosed noncurrent liabilities | 96,338 | ||||||||
| Total noncurrent liabilities: | 217,503 | 50,150 | 50,149 | 19,925 | 19,887 | 19,874 | |||
| Total liabilities: | 265,849 | 64,924 | 58,841 | 28,937 | 30,836 | 46,397 | |||
| Equity | |||||||||
| Equity, attributable to parent | 168,274 | 224,988 | 249,283 | 263,533 | 273,093 | 276,749 | |||
| Common stock | 42,771 | 42,771 | 42,771 | 41,753 | 41,753 | 41,753 | |||
| Treasury stock, value | (1,203) | (1,282) | (1,517) | (746) | (975) | (1,208) | |||
| Additional paid in capital | 616,618 | 602,497 | 601,063 | 601,180 | 596,059 | 590,915 | |||
| Accumulated other comprehensive loss | (4,601) | (4,601) | (4,601) | (4,601) | (4,601) | (4,601) | |||
| Accumulated deficit | (485,311) | (414,397) | (388,433) | (374,053) | (359,143) | (350,110) | |||
| Total equity: | 168,274 | 224,988 | 249,283 | 263,533 | 273,093 | 276,749 | |||
| TOTAL LIABILITIES AND EQUITY: | 434,123 | 289,912 | 308,124 | 292,470 | 303,929 | 323,146 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Gross profit: | ||||||||
| Operating expenses | (68,423) | (27,198) | (19,094) | (16,311) | (9,965) | (22,199) | ||
| Operating loss: | (68,423) | (27,198) | (19,094) | (16,311) | (9,965) | (22,199) | ||
| Nonoperating income (expense) | (1,398) | 2,158 | 4,909 | 1,668 | 1,468 | 5,629 | ||
| Investment income, nonoperating | 3,140 | 3,378 | 3,292 | 3,390 | 3,402 | 2,677 | ||
| Gain, foreign currency transaction, before tax | 1,866 | |||||||
| Interest and debt expense | (3,653) | (1,586) | (623) | (401) | (740) | (293) | ||
| Loss from continuing operations before equity method investments, income taxes: | (73,474) | (26,626) | (14,808) | (15,044) | (9,237) | (16,863) | ||
| Other undisclosed income from continuing operations before income taxes | 3,653 | 1,586 | 623 | 401 | 740 | 293 | ||
| Loss from continuing operations before income taxes: | (69,821) | (25,040) | (14,185) | (14,643) | (8,497) | (16,570) | ||
| Income tax expense (benefit) | (1,014) | (754) | 53 | (44) | (310) | (173) | ||
| Net loss available to common stockholders, diluted: | (70,835) | (25,794) | (14,132) | (14,687) | (8,807) | (16,743) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (70,835) | (25,794) | (14,132) | (14,687) | (8,807) | (16,743) | ||
| Comprehensive loss, net of tax, attributable to parent: | (70,835) | (25,794) | (14,132) | (14,687) | (8,807) | (16,743) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.